Method of Making a Pharmaceutical Composition Comprising a p80 Protein
Summary
USPTO published patent application US20260092087A1 by Prime Bio, Inc. covering a method for producing recombinant p80 polypeptide using E. coli culture with L-Arabinose induction. The p80 protein functions as a tight junction modulator to enhance intestinal permeability for therapeutic agents. The application (No. 19352451) was filed October 7, 2025.
What changed
Prime Bio, Inc. has filed a patent application for a method of manufacturing a pharmaceutical composition containing recombinant p80 protein. The method involves transforming E. coli host cells with an expression vector encoding p80, then inducing expression by adding 0.2% L-Arabinose. The resulting p80 polypeptide acts as a tight junction modulator to enhance permeability of intestinal epithelium, enabling improved transportation of bound therapeutic agents (including drugs, proteins, and biomolecules) into the bloodstream.
This is a routine patent publication that does not impose immediate regulatory obligations. Compliance teams do not need to take action at this stage. Legal and R&D departments should note the specific expression method and therapeutic applications disclosed, particularly the focus on oral delivery enhancement via tight junction modulation. Patent prosecution typically takes 2-3 years before any granted rights could affect freedom-to-operate assessments.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method of Making a Pharmaceutical Composition Comprising a p80 Protein
Application US20260092087A1 Kind: A1 Apr 02, 2026
Assignee
Prime Bio, Inc.
Inventors
Bal Ram Singh, Raj Kumar
Abstract
Present invention relates to a method of making a recombinant p80 polypeptide using an E. coli culture comprising a plurality of E. coli host cells each transformed or transfected with an expression vector containing a DNA fragment encoding a recombinant p80 polypeptide; and inducing the E. coli culture by adding a 0.2% L-Arabinose. The isolated, recombinant p80 is added to a pharmaceutical composition, wherein it binds to a therapeutic agent comprising one or more of: drugs, dyes, small molecules, biomolecules, proteins or a combination thereof. The p80 polypeptide enhances the transportation of the therapeutic agent into the bloodstream by the p80 functioning as a tight junction modulator to enhance the permeability of the intestinal epithelium to the therapeutic agent.
CPC Classifications
C07K 14/33 A61K 45/06 C07K 1/18 A61K 38/00
Filing Date
2025-10-07
Application No.
19352451
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Peptides (C07K) publishes new changes.